Cristal Therapeutics and Intravacc Announce Strategic Partnership
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Cristal Therapeutics and Intravacc Announce Strategic Partnership

By Pharma Tech Outlook | Wednesday, January 13, 2021

Under the terms of the deal, Cristal Therapeutics and Intravacc will coordinate with the initial goal of producing a CriVac vaccine candidate based on the SARS-CoV-2 spike protein binding receptor domain.

FREMONT, CA: Intravacc, a global leader in translational testing and vaccine development, and Cristal Therapeutics, a technological leader in enabling safer and more efficient therapeutics, announced a strategic partnership to create new vaccine programs against human diseases with an initial candidate targeting COVID-19. Under the terms of the deal, Cristal Therapeutics and Intravacc will coordinate with the initial goal of producing a CriVac vaccine candidate based on the SARS-CoV-2 spike protein binding receptor domain.

Moreover, Cristal Therapeutics will supply its strong copper-free click chemistry reagent, CliCr, to evaluate Intravacc's patented Outer Membrane Vesicles (OMV) technology. Vaccines with OMV facilitate the native development of immuno-stimulating antigens. Following the assessment phase's conclusion, Intravacc and Cristal will collectively discuss the next steps to advance the program further.

Intravacc will also have access to its patented, detoxified LPS technology as part of this deal to improve immune activation. Both developments represent revolutionary approaches to vaccine production, allowing a successful presentation of antigens to the immune system. The fusion of technologies would further allow the accelerated production of vaccine candidates against a wide variety of human diseases. In specific, this is driven by a flexible GMP manufacturing mechanism.

CriVac, Cristal's patented vaccine platform, integrates the tuneability and ease of processing of biodegradable CriPec nanoparticles with CliCr conjugation technology for the rapid and regulated conjugation of antigens on the surface of the nanoparticle. On the other hand, CliCr is a family of fast-reacting molecular entities for conjugating compounds to one another in a strain-promoted azide-alkyne cycloaddition click reaction. CliCr is capable of binding a diverse variety of small molecule active agents and large molecular organisms, including biologics, to CriPec nanoparticles. Attractive functionalization options, together with simplicity, high reactivity, and small scale, give several possibilities for CliCr reagents to become the modern standard for non-copper catalyzed click reactions in a wide variety of applications.

Weekly Brief

Read Also